Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brincidofovir - Chimerix/Emergent Biosolutions

Next Previous
X
Search
Drug Profile

Brincidofovir - Chimerix/Emergent Biosolutions

Alternative Names: BCV; BCV-001; Cidofovir hexadecyloxypropyl ester; Cidofovir PIM conjugate; CMX-001; CMX001-129; HDP-CDV; HDP-cidofovir; Hexadecyl-oxypropyl cidofovir - Chimerix; SyB-V-1901; TEMBEXA

Latest Information Update: 16 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Brown University; Centers for Disease Control and Prevention; Chimerix; Emergent BioSolutions; National Cancer Centre (Singapore); National Institute of Neurological Disorders and Stroke; National Institutes of Health (USA); SymBio Pharmaceuticals; University of California at San Francisco; University of Oxford
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections; Smallpox; Adenovirus infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Smallpox
  • Phase III Cytomegalovirus infections
  • Phase II/III Viral infections
  • Phase II Adenovirus infections; Human polyomavirus infections
  • Preclinical B-cell lymphoma; Epstein-Barr virus infections; Glioblastoma
  • No development reported Herpes simplex virus infections; Monkeypox
  • Discontinued Ebola virus infections

Most Recent Events

  • 05 Apr 2024 Preclinical trials in B-cell lymphoma in Japan (unspecified route), before April 2024
  • 05 Apr 2024 Pharmacodynamics data from preclinical trial in B cell lymphoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in Japan (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top